Literature DB >> 27340089

Behavioral deficits and cholinergic pathway abnormalities in male Sanfilippo B mice.

Shih-Hsin Kan1, Steven Q Le1, Quang D Bui1, Braeden Benedict1, Jesse Cushman2, Mark S Sands3, Patricia I Dickson4.   

Abstract

Sanfilippo B syndrome is a progressive neurological disorder caused by inability to catabolize heparan sulfate glycosaminoglycans. We studied neurobehavior in male Sanfilippo B mice and heterozygous littermate controls from 16 to 20 weeks of age. Affected mice showed reduced anxiety, with a decrease in the number of stretch-attend postures during the elevated plus maze (p=0.001) and an increased tendency to linger in the center of an open field (p=0.032). Water maze testing showed impaired spatial learning, with reduced preference for the target quadrant (p=0.01). In radial arm maze testing, affected mice failed to achieve above-chance performance in a win-shift working memory task (t-test relative to 50% chance: p=0.289), relative to controls (p=0.037). We found a 12.4% reduction in mean acetylcholinesterase activity (p<0.001) and no difference in choline acetyltransferase activity or acetylcholine in whole brain of affected male animals compared to controls. Cholinergic pathways are affected in adult-onset dementias, including Alzheimer disease. Our results suggest that male Sanfilippo B mice display neurobehavioral deficits at a relatively early age, and that as in adult dementias, they may display deficits in cholinergic pathways.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acetylcholinesterase; Glycosaminoglycan; Inborn error of metabolism; Lysosomal; Mucopolysaccharidosis; Neurodegeneration

Mesh:

Substances:

Year:  2016        PMID: 27340089      PMCID: PMC4970944          DOI: 10.1016/j.bbr.2016.06.023

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  30 in total

1.  Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment.

Authors:  D C Rogers; E M Fisher; S D Brown; J Peters; A J Hunter; J E Martin
Journal:  Mamm Genome       Date:  1997-10       Impact factor: 2.957

2.  Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.

Authors:  Coy D Heldermon; Kevin K Ohlemiller; Erik D Herzog; Carole Vogler; Elizabeth Qin; David F Wozniak; Yun Tan; John L Orrock; Mark S Sands
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

3.  Bright light suppresses hyperactivity induced by excitotoxic dorsal hippocampus lesions in the rat.

Authors:  Bill P Godsil; Lisa Stefanacci; Michael S Fanselow
Journal:  Behav Neurosci       Date:  2005-10       Impact factor: 1.912

4.  Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.

Authors:  Shih-Hsin Kan; Mika Aoyagi-Scharber; Steven Q Le; Jon Vincelette; Kazuhiro Ohmi; Sherry Bullens; Daniel J Wendt; Terri M Christianson; Pascale M N Tiger; Jillian R Brown; Roger Lawrence; Bryan K Yip; John Holtzinger; Anil Bagri; Danielle Crippen-Harmon; Kristen N Vondrak; Zhi Chen; Chuck M Hague; Josh C Woloszynek; Diana S Cheung; Katherine A Webster; Evan G Adintori; Melanie J Lo; Wesley Wong; Paul A Fitzpatrick; Jonathan H LeBowitz; Brett E Crawford; Stuart Bunting; Patricia I Dickson; Elizabeth F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

5.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

6.  Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery.

Authors:  Haiyan Fu; Julianne DiRosario; Lu Kang; Joseph Muenzer; Douglas M McCarty
Journal:  J Gene Med       Date:  2010-07       Impact factor: 4.565

7.  Automated apparatus for quantitation of social approach behaviors in mice.

Authors:  J J Nadler; S S Moy; G Dold; D Trang; N Simmons; A Perez; N B Young; R P Barbaro; J Piven; T R Magnuson; J N Crawley
Journal:  Genes Brain Behav       Date:  2004-10       Impact factor: 3.449

8.  Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice.

Authors:  H Fu; L Kang; J S Jennings; S S Moy; A Perez; J Dirosario; D M McCarty; J Muenzer
Journal:  Gene Ther       Date:  2007-04-26       Impact factor: 5.250

Review 9.  Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder.

Authors:  Frits A Wijburg; Grzegorz Węgrzyn; Barbara K Burton; Anna Tylki-Szymańska
Journal:  Acta Paediatr       Date:  2013-02-06       Impact factor: 2.299

10.  Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice.

Authors:  D M McCarty; J DiRosario; K Gulaid; J Muenzer; H Fu
Journal:  Gene Ther       Date:  2009-07-09       Impact factor: 5.250

View more
  4 in total

1.  MPS-IIIA mice acquire autistic behaviours with age.

Authors:  Adeline A Lau; Sarah J Tamang; Kim M Hemsley
Journal:  J Inherit Metab Dis       Date:  2018-03-08       Impact factor: 4.982

2.  CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β-Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease.

Authors:  Rima Rebiai; Emily Rue; Steve Zaldua; Duc Nguyen; Giuseppe Scesa; Martin Jastrzebski; Robert Foster; Bin Wang; Xuntian Jiang; Leon Tai; Scott T Brady; Richard van Breemen; Maria I Givogri; Mark S Sands; Ernesto R Bongarzone
Journal:  Front Mol Neurosci       Date:  2022-05-10       Impact factor: 6.261

3.  Myelin and Lipid Composition of the Corpus Callosum in Mucopolysaccharidosis Type I Mice.

Authors:  Steven Q Le; Igor Nestrasil; Shih-Hsin Kan; Martin Egeland; Jonathan D Cooper; David Elashoff; Rong Guo; Jakub Tolar; Jennifer K Yee; Patricia I Dickson
Journal:  Lipids       Date:  2020-06-14       Impact factor: 1.880

4.  Describing the dynamic translational science landscape through Core Voucher utilization.

Authors:  Elvira L Liclican; Scott G Filler; Jonathan Kaye; Christopher T Denny
Journal:  J Clin Transl Sci       Date:  2019-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.